Advice

Following a full submission.

Omalizumab (Xolair®) is not recommended for use within NHS Scotland as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) with severe persistent allergic asthma.

The economic case for omalizumab has not been demonstrated.

The licence holder has indicated their decision to resubmit.

Download detailed advice111KB (PDF)

Download

Medicine details

Medicine name:
Omalizumab 150mg powder and solvent for injection (Xolair)
SMC ID:
259/06
Indication:
Asthma
Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Full
Status
Superseded
Date advice published
12 June 2006